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Abstract
Background: In Scotland a new, easier to complete bowel screening test, the Faecal Immunochemical Test (FIT),
has been introduced. This test gives more accurate information about an individual’s risk of having colorectal
cancer (CRC), based on their age and gender, and could lead to fewer missed cancers compared to the current
screening test. However, there is no evidence of the effect on colonoscopy uptake of providing individuals with
personalised risk information following a positive FIT test.
The objectives of the study are:
1) To develop novel methods of presenting personalised risk information in an easy-to-understand format using
infographics with involvement of members of the public
2) To assess the impact of different presentations of risk information on informed choice and intention to take
up an offer of colonoscopy after FIT
3) To assess participants’ responses to receiving personal risk information (knowledge, attitudes to screening/risk,
emotional responses including anxiety).
Methods: Adults (age range 50–74) registered on the Scottish Bowel Screening database will be invited by letter to
take part. Consenting participants will be randomised to one of three groups to receive hypothetical information
about their risk of cancer, based on age, gender and faecal haemoglobin concentration: 1) personalised risk
information in numeric form (e.g. 1 in 100) with use of infographics, 2) personalised information described as
‘highest’, ‘moderate’ or ‘lowest’ risk with use of infographics, and 3) as a ‘positive’ test result, as is current practice.
Groups will be compared on informed choice, intention to have a colonoscopy, and satisfaction with their decision.
Follow-up semi-structured qualitative interviews will be conducted, by telephone, with a small number of
consenting participants (n = 10 per group) to explore the acceptability/readability and any potential negative
impact of the risk information, participants’ understanding of risk factors, attitudes to the different scenarios, and
reasons for reported intentions.
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Discussion: Proving personalised risk information and allowing patient choice could lead to improved detection of
CRC and increase patient satisfaction by facilitating informed choice over when/whether to undergo further
invasive screening. However, we need to determine whether/how informed choice can be achieved and assess the
potential impact on the colonoscopy service.
Trial registration: The trial is registered on www.isrctn.com on 08/12/2017. Registration no: ISRCTN14254582.
Keywords: Colorectal cancer, Informed choice, Bowel screening, Colonoscopy, Personalised risk information
Background
In Scotland, the guaiac Faecal Occult Blood Test
(gFOBT) has recently been replaced by a quantitative
Faecal Immunochemical Test for haemoglobin (FIT) in
the bowel cancer screening programme, after a success-
ful demonstration pilot of “FIT as a First-Line Test”. FIT
will initially be used with a faecal haemoglobin concen-
tration of 80 μg Hb/g faeces in order to achieve approxi-
mately 2% positivity, to mimic the screening algorithm
based on the previous two-tier reflex gFOBT/qualitative
FIT strategy. However, FIT (along with age/gender)
could provide a more personalised risk of harbouring
advanced neoplasia (colorectal cancer (CRC) or high risk
adenoma), and thus empower people to make an in-
formed decision about whether or not to undergo colon-
oscopy, by balancing the risks of the procedure (e.g.
bleeding/bowel wall perforation) against the risk of miss-
ing a cancer. This is particularly important in CRC
screening. Currently, about half of all cancers in the
screened population are diagnosed in the interval be-
tween screening rounds, indicating that, at the current
threshold, the test is only about 50% sensitive for colo-
rectal cancer. Reducing the threshold would result in
fewer cancers being missed but would increase the
chance of a negative colonoscopy and the impact on the
colonoscopy service may be unsustainable. Thus, we aim
to investigate the potential implications of providing the
screened population with a more informed choice to
help establish the impact on colonoscopy services.
This early phase study aims to assess patient responses
to personalised risk information about their estimated
risk of having colorectal cancer. Screened participants
will be randomised to receive hypothetical scenarios of
personalised risk information based on age, gender and
haemoglobin concentration; or to treatment as usual, i.e.
a positive/negative test result based on approximately
2% positivity (i.e. the proportion of screened individuals
with a positive result). The best methods to present this
information will be determined by this study. Study arms
will be compared on level of informed choice achieved
and intention to undergo colonoscopy and satisfaction
with the decision made. Thus, we will assess the poten-
tial impact on colonoscopy services of introducing per-
sonalised risk information and whether informed choice
can improve patient outcomes/satisfaction. The results
will be used to inform a full-scale randomised controlled
trial (RCT) to evaluate uptake of colonoscopy for Scot-
tish Bowel Screening programme participants. The inter-
vention could be low-cost to deliver at scale, and thus
prove cost-effective for introduction within the national
screening programme.
In order to inform a large population-based study, we
must first assess the optimal method of delivering infor-
mation for a truly informed choice. There is a dearth of
current evidence. A recent Cochrane systematic review
examined the effect of personalised risk communication
for informed decision-making in uptake of medical
screening compared to general information [1]. Overall,
providing a numerical risk score or a categorised risk
(e.g. ‘low’, ‘medium’, ‘high’) increased informed choice
(odds ratio: 3.65 (95% C.I. 2.13 to 6.23), for random ef-
fects and screening uptake (odds ratio: 1.15 (95% C.I.
1.02 to 1.29)). However, the included studies covered a
wide range of screening tests and thus the results were
heterogeneous. Of the studies involving CRC, only one
used a calculated numerical risk score, leading to greater
knowledge but non-significant lower intention and up-
take; it did not report changes in informed choice [2].
Three studies used a categorised risk score; these did
not assess knowledge or informed choice, but indicated
a small, significant increase in uptake of screening [3–5].
The authors concluded that the evidence that persona-
lised risk communication increases screening uptake is
weak. Further, although some included colonoscopy, all
of the reviewed studies involving CRC screening related
to first line screening only.
There is thus no existing evidence on the effects of
personalised risk information on uptake of colonoscopy
following first line screening for CRC. Our study would
fill this knowledge gap. It will develop a novel persona-
lised risk information intervention to enable national
bowel screening programme participants to make an in-
formed choice about having a colonoscopy following a
FIT result with detected haemoglobin, by weighing their
personalised risk versus the risks/disadvantages of colon-
oscopy. The proposed study has the potential to: 1) pro-
vide individuals with truly informed choice based on
their own risk level, 2) reduce the number of ‘missed’
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interval cancers by offering colonoscopy at lower thresh-
olds than the current cut-off, 3) improve patient out-
comes and satisfaction. We will determine the best
methods for achieving informed choice and, if success-
ful, they would have the potential to be extended to
other screening/treatment scenarios, and thus have
much wider impact. The study outcomes would give in-
dicative effects to inform a larger RCT designed to pro-
vide evidence on any impact on colonoscopy services.
This research will deliver new knowledge about the
impact of personalised risk information on delivering in-
formed choice for colonoscopy and has the potential to
benefit NHS managers and policy makers, cancer char-
ities, members of the public, behavioural scientists and
academics interested in health behaviour and informed
choice.
Providing patients with informed choice is a core NHS
tenet yet there is little evidence on its impact on CRC
screening uptake. We believe this research could lead to
improved detection of CRC, improve health outcomes
and save lives. If results are promising, it would be feas-
ible to present risk information in the format(s) devel-
oped in this research project within the scope of the
Scottish bowel screening programme in the future. Thus
it has the potential to increase patient satisfaction by
helping them to make their own informed decision over
when or whether to undergo invasive screening. Al-
though there could be increased costs to the NHS due
to increased colonoscopy uptake; earlier cancer detec-
tion could ultimately reduce NHS treatment costs and
would contribute towards meeting the aim of the Detect
Cancer Early Programme to improve 5-year survival.
In the longer-term, the intervention could be adapted
for other settings where individualised information may
be available including medical screening, treatment deci-
sions and in promoting lifestyle changes to reduce future
health risks, and so it has the potential for much wider
impact. It is proposed that any follow-up study should
include GP interactions, as patients receiving a positive
FIT result may seek advice from their GP in making an
informed decision about colonoscopy.
The aims of this study are:
1) To develop methods of presenting personalised risk
information to Scottish Bowel Screening
Programme participants, in an easy-to-understand
format using infographics.
2) To assess the impact of different presentations of
risk information on informed choice and intention
to take up an offer of colonoscopy after FIT.
3) To assess participants’ responses to receiving
personal risk information, including knowledge,
attitudes to screening and risk, and emotional
responses including anxiety.
Methods
A simple 3-arm RCT design will be used for an inter-
vention to present different levels of personalised risk
and its effect on informed choice and intention to take
up an offer of colonoscopy. The three groups are: 1) nu-
merical personalised risk information, 2) categorical risk
information, 3) positive screening test result. This is a
single centre study covering the whole of Scotland and
based at NHS Tayside, Ninewells Hospital & Medical
School in Dundee.
Table 1 lists the objectives, hypothesis and variables,
analysis techniques and anticipated conclusions of the
study.
Recruitment will be carried out by the Research Fellow
(RF). Adults registered on the Scottish National Bowel
Screening Programme database (age range 50–74 years)
will be purposely selected to represent all age ranges, all
deprivation categories and both genders as these factors
have been shown to be associated with screening uptake.
As it is typical in questionnaire-based research to get
more responses from some groups (e.g. older people and
higher socio-economic groups), the target recruitment
will be weighted towards those groups who may be less
likely to participate, based on response levels obtained
from our large-scale questionnaire study on bowel
screening [6], with the aim of achieving a balanced sam-
ple of participants.
Prospective participants would be approached, by let-
ter, sent on behalf of the Principal Investigator (PI), Dir-
ector of the Scottish Bowel Screening Programme, to
ask if they would like to participate in a survey to assess
their response to an offer of colonoscopy in relation to
an estimated personalised risk of having cancer. A full
patient information sheet and a response form will be
included along with a pre-paid envelope for return. In
line with published criteria for increasing recruitment
[7], we would use techniques including personally ad-
dressed invitation letters, signed by the PI, stamped ra-
ther than franked return envelopes, and coloured ink.
The participants would also be asked whether or not
they would consent to taking part in a short follow-up
interview by telephone. A response form will give the
option to provide a telephone number if they are happy
to being contacted in this way along with the postal
address to receive the study risk materials with the ques-
tionnaire. Those not replying are assumed to have de-
clined to participate. On receipt of the returned
completed response form, it would be considered that
the patient is in the study and would be randomised to
receive the study materials. Return of the completed
questionnaire will be considered as an implied consent.
Verbal consent will be confirmed at the start of the tele-
phone interview, including consent for audio-recordings.
The consent form will be read and audio recorded along
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with patient replies which will also be ticked on paper.
Participants can still take part in the telephone interview,
even if they do not wish to be recorded, in which case
responses would be recorded on paper. A study ID will be
assigned prior to transcription to ensure the interview is
anonymised. The consent form will be stored separately to
the anonymised study data.
A designated contact person who is external to the
study team has also been nominated if prospective par-
ticipants wish to discuss any concerns that invitees may
have regarding the study before giving consent. The Pa-
tient Information Sheet will make clear that participants
may withdraw from the study at any time without giving
a reason and their data will be removed from the study.
Based on previous research [8], it is expected that 25%
will respond and be randomised, we expect a further
20% attrition between consent and questionnaire return.
The risk information materials will initially be pilot
tested in around 30 participants from the screening
database. Therefore, 144 will be invited, with 36 ex-
pected to respond and 30 completing the questionnaire.
Following the pilot testing in sample participants, a
further 1440 will be invited to receive the finalised per-
sonalised risk information about their risk of having
colorectal cancer and provide responses. As above, it is
expected that 360 will respond and be randomised, with
300 then completing the study questionnaire. Figure 1
shows a flow diagram of the study design with expected
numbers of participants. A small number of participants
would be purposively sampled, from those consenting to
be telephoned, from each treatment arm, estimated at 10
per arm, total = 30, to provide representation with regard
to age, gender, socioeconomic status and responses to
the scenarios.
Any adult registered on the Scottish Bowel Screening
database with ability to consent (aged 50–74 years) will
be included in the participant selection, but invitations
will not be sent to those who have recently participated
in screening, or will shortly be invited for screening
(within six months of either event). This is to avoid any
potential confusion between the study materials and the
actual screening result.
For ethical reasons, the Study Participant Information
Sheet will state that those currently being treated for
cancer or other serious illness should ignore the invita-
tion and accept our apologies for contacting them at
what may be an inappropriate time. Inclusion on the
screening database coincides with the first invitation at
age 50, thus it is not possible to sample those not previ-
ously invited. Prospective participants would therefore
include those who have previously been invited but not
taken part in screening, those who have previously com-
pleted a gFOBt or FIT test, and also potentially a small
number who have previously had a positive test and
been offered colonoscopy.
Our aim is to develop novel, personalised risk infor-
mation materials (for both risk of having CRC and risk
of undergoing colonoscopy) which will be provided in a
Table 1 Study Matrix
Objective Hypothesis Variables Techniques of
analysis
Anticipated
Conclusions
1) Level of informed
choice (derived from
knowledge, attitudes,
informed subscore of
Decisional Conflict Scale).
2) Development of novel,
personalised risk information
materials.
3) Intention to take up an
offer of colonoscopy.
Providing personalised risk
information will provide
individuals with truly informed
choice based on their own risk
level and improve satisfaction in
screening participants.
• Age
• Gender
• SIMD
• Study arm
• Previous screening history
• Measures of
informed choice:
° Knowledge
° Attitude
° Informed subscore
(Decisional Conflict Scale)
• Behaviour (intention to
uptake colonoscopy)
• Anxiety
Comparison of
knowledge,
attitudes and
intention to
uptake
colonoscopy
between the study arms.
Data on intention to take
up colonoscopy from
each scenario will be
matched with the expected
range of risk scores in the
Scottish population.
Comparison of themes
from the qualitative analysis
between those who intended
and did not intend to take up
the offer of colonoscopy.
Any differences with respect to
age/gender/
socioeconomic status and also
whether or not previously
participated in screening
and/or taken up the offer
of colonoscopy would
also be explored.
Differences in
intention to uptake
colonoscopy between
study arms will help
to inform a full-scale
RCT to evaluate up-
take of colonoscopy
in Scottish Bowel
Screening Programme
participants.
SIMD Scottish Index of Multiple Deprivation
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visual format (based on infographics [9]), aimed at being
understandable across education levels, as guided by rec-
ommendations [10, 11]. It is planned to use absolute
instead of relative risks, mortality instead of survival
rates, and natural frequencies instead of conditional
probabilities, as these are recommended as best practice
Fig. 1 CONSORT diagram
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[12]. However, this is open to change if the development
process suggests otherwise.
The risk information materials for each of the study
arms will be developed in months 1–12. We will recruit
2 Public and Patient Involvement (PPI) representatives
to be core members of our project team and a further
4–6 PPI representatives to participate in co-development
workshops along with the RF, the core project team and
an infographics expert who has been engaged to design
and produce the risk materials. The materials will then
be pilot tested on sample participants before being re-
fined and finalised.
The PPI participants will be from a healthy population
group. They will be selected to be representative of the
screening population with regard to socioeconomic sta-
tus, age and gender. Those with a diagnosis of colorectal
cancer will be excluded as it is important for the mate-
rials to be relevant to asymptomatic people who do not
have a diagnosis of colorectal cancer. Medically qualified
people will also be excluded. They will be sought via
routes such as SHARE, the NHS Public Involvement
Team and through other academic contacts with appro-
priate patient representative groups in place who might
be interested in participating in this work.
The co-development workshops will be held
throughout months 3–12 to develop, review and
refine the project materials. We estimate that this
would involve up to six three-hour meetings, which
will be held at a venue convenient to the PPI group.
Travel and subsistence costs will be met in full. As
key members of the workshops, the PPI participants
will contribute to the development process from a lay
perspective, as health professionals and patients may
form different interpretations of risk information.
They will also provide feedback on the modified in-
formed choice measure. We do not think it necessary
to audio record the discussions; however, the RF will
minute key points and circulate to the group follow-
ing each meeting.
The risk materials will be pilot tested with a small
sample (n = 30) of participants from the screening
database, who would be posted the study invitation
letter with reply slip, patient information sheet, risk
information materials and informed choice question-
naire in advance of the main recruitment (month 7).
An option to consent to telephone contact is available
on the reply slip. Telephone interviews (months 8–9)
will be conducted with consenting participants to
assess ease of understanding and acceptability, and
understanding of levels or risk based on the different
scenarios. The impact on informed choice via the
developed measure will also be assessed. The results
will be fed into the finalisation of the materials, at a
workshop involving the PPI members (month 10).
Presentation or risk will be assessed both as a ‘1 in x
risk’ and natural frequencies in the development process,
one or both of these may be used in the final materials.
Participants will also be presented with the information
on the risks of having a colonoscopy which is currently
provided to those who are offered the test following a
positive gFOBT. Group 3 is effectively a control group,
which reflects current practice, to allow comparison of
likely uptake of colonoscopy with the personalised risk
information groups. Three verbal categories (lowest,
moderate, highest risk) for simplicity of presentation of
information are proposed. However, it is possible this
could be modified during the development process, if
the PPI involvement suggests otherwise. The develop-
ment of the risk materials is a key part of the project,
thus it is not possible to be too specific on detailed con-
tent or categorisations at this stage. The finalised risk
materials will be used in the RCT across Scotland.
Patients who complete and return the response form
indicating that they are willing to take part will be ran-
domised to one of the study arms and then posted the
materials and informed choice questionnaire with a
stamped addressed envelope for return of the question-
naire. Study documents which will be sent to the partici-
pant are: Scenario letter(s) according to study arm, study
questionnaire, “Having a colonoscopy” leaflet and “The
Bowel Screening Test” leaflet. Return of the question-
naire will be considered as an implied consent.
Randomisation with minimisation on variables related
to risk (i.e. age, SIMD, gender) will be carried out via
MINIM software by an individual independent to the
process of running the study, who will thus be blinded
to the recruitment process.
The study will be co-ordinated by a Study Manage-
ment Group, consisting of the PI, Co-investigators, Re-
search Fellow and two PPI members.
Consenting participants will be randomised to one of
3 conditions:
1) Numerical (i.e. a personalised numerical-based risk
assessment (e.g. 1 in x risk) related to hypothetical
test result and age and gender)
2) Categorical (as treatment group 1) but this would
be categorised as ‘Lowest’, ‘Moderate’ and ‘Highest’
risk
3) Positive cut-off (i.e. as current practice that is i.e. a
positive test result, based on the current cut-off to
give approximately 2% positivity).
Each condition would be presented with hypothetical
scenarios relating to different levels of risk of CRC and
asked to rate their intention of attending a colonoscopy
if they received that result following an actual FIT.
Three scenarios, relating to lowest, moderate and
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highest risk for colorectal cancer would be presented in
groups 1 and 2; by definition group 3 has only one pos-
sible scenario i.e. a positive screening test result.
The lowest, moderate and highest risk categories and
the disease frequencies used in the scenarios will be de-
rived from data from a study which observed that risk of
significant colorectal neoplasia rises with increasing fae-
cal haemoglobin concentrations [13]. Although the ac-
tual faecal haemoglobin concentrations might represent
different risks for individuals (e.g. different genders), the
hypothetical scenarios would be presented as a specific
level of risk (e.g. with this result you would have a 1 in x
risk (or a moderate risk) of having CRC) and thus would
be applicable to all participants. The aim of using both
actual numerical risks and verbal categories is to assess
their impact on the understanding and reactions of par-
ticipants to these different forms of materials. The
standard information describing the first-line screening
process will be provided as an introduction to the differ-
ent scenarios, as participants may have different previ-
ous experiences of first line screening.
A study questionnaire will be used to collect partici-
pant responses to information materials including
intention, knowledge about the test (8 items: including
risks of having cancer and undergoing a colonoscopy)
and attitudes towards undergoing the test (4 items: in-
cluding benefits, importance and pleasantness/ unpleas-
antness) and anxiety. Questionnaire data will be
collected at a single time-point (months 19–21). Tele-
phone interviews will be conducted in a small number
of participants (10 from each study arm) to collect more
detailed responses.
Data on screening history (i.e. previous participation/
failure to participate/been offered a colonoscopy) will be
collected at the time of sampling, as these strongly pre-
dict screening uptake [6]. We accept that recruitment
via invitation letter may lead to a bias towards previous
screening participants in our sample. However, in actual
practice, the offer of informed choice following FIT
would only be made to those who had completed the
test with detected blood in their sample, so we believe
this would be an acceptable, if not desirable, bias. How-
ever, as FIT has just been introduced in Scotland and
the previous gFOBt is thought to be regarded as more
difficult to complete [14], we would not want to exclude
people who may complete a FIT in the future. Any dif-
ferences with regard to previous screening history would
be explored in our analysis (see below).
There is as yet no accepted measure of informed
choice in cancer screening uptake [12]. Our informed
choice measure will be adapted from Smith et al. [9].
They applied a multidimensional model of informed
choice (developed and validated for antenatal screening
for Down’s syndrome [15, 16], and combined the
constructs of a) knowledge, b) attitudes and c) behaviour
to assess the extent to which people made an informed
choice about participating in screening using gFOBT.
Items measuring knowledge about the test (8 items: in-
cluding risks of having cancer and undergoing a colon-
oscopy) and attitudes towards undergoing the test (4
items: including benefits, importance and pleasantness/
unpleasantness) will be adapted to relate to colonoscopy
rather than gFOBT. As this is therefore a new scale, the
measure will be pilot tested with the PPI project partici-
pants, workshop participants and a small sample of par-
ticipants from the bowel screening database (the same
sample as in development of risk materials above) to as-
sess acceptability and understanding. Full psychometric
testing of the developed measure will be undertaken and
reported.
We will use the informed subscore (items 1–3) from
the Decisional Conflict Scale [17] to assess the extent to
which participants feel informed about their decisions.
These items are: “I know which options are available to
me”, “I know the benefits of each option” and “I know
the risks and side effects of each option”, scored on a
7-point scale from “strongly agree” to “strongly dis-
agree”. As this is a hypothetical scenario study we are
only able to use intention and not actual uptake as our
outcome measure of behaviour. However, intention was
very strongly related to actual uptake (with a mean
intention score of 6.7 out of a maximum 7 for kit re-
turners) in our previous large-scale study [6].
Intention to take up the offer of colonoscopy, as a
proxy for behaviour, will be measured on a Likert-type
scale from 1 (low intention) to 7 (strongly intend) in re-
sponse to e.g. “If I received information that I had x level
of risk of bowel cancer, I would choose to have a colon-
oscopy”. Anxiety will be measured by a
previously-validated six-item version of the State Trait
Anxiety Inventory [18]. An example item is the state-
ment “I am worried”, with a choice of four responses on
a scale from “not at all” to “very much”.
Ease of understanding and acceptability of the presen-
tation of risk information will also be assessed in the
questionnaire using Likert-type questions e.g. “I found
the information presented easy to understand” scored on
a 7-point scale from “strongly agree” to “strongly
disagree”.
A small number of participants would be purposively
sampled, from those agreed to be telephoned/consented
for the interview, from each treatment arm (estimate n
= 10 per arm, total n = 30) to provide representation
with regard to age, gender, socioeconomic status and re-
sponses to the scenarios. The RF would conduct
semi-structured interviews, by telephone, to explore the
acceptability/readability and any potential negative im-
pact of the risk information, participants’ understanding
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of risk factors and attitudes to the different scenarios
presented, and reasons for their reported intentions. As
only a small number of the 300 participants will be
interviewed at follow-up, the questionnaire will include
an open-ended final question encouraging additional
comments. The follow-up telephone interviews will in-
clude questions relating to emotional responses to the
material and understanding of what is meant by the ver-
bal risk categories, as well as asking how participants
perceive the risk of undergoing a colonoscopy versus
that of having cancer in the given scenarios.
Telephone interviews are an effective means of
gathering data in health research provided challenges
are addressed [19]; and are more practical and
cost-effective than face-to-face interviews as partici-
pants will be from the whole of Scotland. Interviews
will be recorded (with permission) and fully
transcribed.
All questionnaires and other records will be identified
in a manner designed to maintain participant confidenti-
ality. All records will be kept in a locked filing cabinet
with limited access to study staff only. Archiving of
study documents will be for five years after the end of
study.
Data integrity of questionnaire data will be enforced
by valid and range checks at the time of data entry. Clin-
ical information will not be released without the written
permission of the participant, except as necessary for
monitoring and auditing by the Sponsor or its designee.
All electronic information will be stored on secure net-
work computers held on a University of Dundee net-
work drive accessed by a password protected device.
Data management will be conducted in compliance with
Tayside Medical Science Centre (TASC) Standard Oper-
ating Procedures (SOP) on Data Management, TASC
SOP53 Data Management Systems in Clinical Research.
The Data Management System (DMS) will be Excel, as
approved by Sponsor. The DMS will be based on the
protocol for the study and individual requirements of
the investigators. Information will only be collected that
is required to meet the aims of the trial and to ensure
the eligibility and safety of the participant. The trial
database will be compliant with TASC SOP53 Data
Management Systems in Clinical Research. The anon-
ymised data will be imported from Excel for analysis
using SPSS (see below).
The database is managed in line with all applicable
principles of medical confidentiality and UK law on data
protection, namely, the Data Protection Act 1998, which
brought UK law into line with the EU Data Protection
Directive. The Data Controller will be the University of
Dundee and the Data Custodian will be the PI. Database
lock will be conducted in compliance with TASC SOP32
Locking Clinical Study Databases.
The PI, co-investigators and all institutions involved in
the study will permit study related monitoring, audits,
and Research Ethics Committee review. The PI agrees to
allow the Sponsor or, representatives of the Sponsor,
direct access to all study records and source
documentation.
Knowledge, attitudes and intention to take up colonos-
copy will be compared between the groups, using
pre-determined categorisations [12], to assess whether
providing personalised information on CRC risk leads to
informed choice. In addition, between group differences
in outcomes on the scales relating to knowledge, atti-
tudes and behaviour will be analysed as continuous vari-
ables via Analysis of Variance (ANOVA) and individual
items will also be examined, as recommended by Gha-
nouni et al. [20]. Covariates in the analyses are age, gen-
der, deprivation category, and history of FOBT/FIT
screening, as obtained from the screening database. Data
on personal or family history of CRC are not available in
the screening database and therefore cannot be
examined.
Data on intention to take up colonoscopy from each
scenario will be matched with the expected range of risk
scores in the Scottish population (from the demonstra-
tion pilot of FIT as a First Line Test), to estimate total
uptake, and hence the potential impact on colonoscopy
services for numerical versus categorical presentation of
personalised risk information, in comparison to the
current positive/negative cut-off. This will provide pre-
liminary evidence of the effects of implementing in-
formed choice following introduction of FIT on current
colonoscopy services.
Themes from the qualitative analysis will be compared
between those who intended and did not intend to take
up the offer of colonoscopy, which would help in under-
standing how the personalised risk information for both
CRC and colonoscopy is understood and received and
also the underlying reasons for the choices made. Any
differences with respect to age/gender/socioeconomic
status and also whether or not previously participated in
screening and/or taken up the offer of colonoscopy will
also be explored.
Thematic qualitative analysis will be used to analyse
responses gathered from the telephone interviews as it
permits rich description of participants’ perceptions,
feelings and experiences [21]. Each interview will be ana-
lysed on a line-by-line basis for key themes/patterns.
Recruitment will continue until saturation of themes is
reached. The planned recruitment of n = 30 to the quali-
tative interviews is based on numbers required for satur-
ation in previous research by the authors, but there is
scope to increase this if saturation is not achieved.
An n = 300 (100 in each group) will have 83.7% power
of detecting a 1 point increase in knowledge (intervention
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versus control), and a 2 point difference in attitudes
(based on existing study means/SDs [9, 15]), using a
one-way ANOVA. A pilot sample of 60–100 per group is
recommended to provide an estimate of an event rate [22]
(e.g. screening uptake); so a sample of 300 would provide
an indicative effect size of colonoscopy uptake for a future
full-scale study. We would send out 1440 invitations, from
whom we conservatively expect to get around 360 replies
(25%) (based on previous research [8]); we expect a fur-
ther 20% attrition between consent and questionnaire re-
turn, giving a final n = 300. In the event that we do not hit
our target of 360 replies to the first letter, a second wave
of invitation letters would be sent out (the number of
these would be based on actual response to and the deficit
from the first invitation). We accept that the sample size
may not be sufficient to assess all interactions between
covariates. However this is a pilot study and a major aim
is to assess effect sizes to determine accurate sample sizes
for a larger study; we believe we have sufficient power to
achieve this aim.
There is a risk of causing upset to patients with cancer
or patients who may be disturbed by thinking about
their cancer risk. It is not possible to exclude such
patients from the initial contact. We have worded the
Participant Information Sheet to express our apologies
for contacting anyone in inappropriate circumstances.
The patient invitation letter provides contact details of
an individual who is completely independent of the re-
search who can help in this case and advise to whom a
complaint can be made to if required. It will also be
stressed that risk scenarios are purely hypothetical. It
should be noted that all individuals who will be con-
tacted are enrolled in screening and the invite would not
be dissimilar to the Scottish Bowel Screening invite.
If there is a problem with any participant it will be re-
corded in an Adverse Event log in compliance with
TASC SOP11v9.
The PI will seek approval for any amendments to the
Protocol or other study documents from the Sponsor,
Research Ethics Committee (REC) and NHS R&D Of-
fice(s). Amendments to the protocol or other study docs
will not be implemented without these approvals.
In the event that the PI needs to deviate from the
protocol, the nature of and reasons for the deviation will
be recorded in the Case Report Form, documented and
submitted to the Sponsor. If this necessitates a subse-
quent protocol amendment, this will be submitted to the
Sponsor for approval and then to the appropriate REC
and lead NHS R&D Office for review and approval. In
the event that a serious breach of Good Clinical Practice
(GCP) or protocol is suspected, this will be reported to
the Sponsor Governance Office immediately.
Annual reporting will be conducted in compliance
with TASC SOP 15: Preparing and Submitting Progress
and Safety Reports in CTIMPs and Non-CTIMPs, as a
condition of sponsorship and as a condition of a
favourable opinion from a REC. An HRA Annual Pro-
gress Report for NCTIMPs will be prepared and submit-
ted by the CI to REC, and copied to the Sponsor, on the
anniversary date of the REC favourable opinion.
Any safety reports additional to Serious Adverse Event
reports, for example, reports of a Data Monitoring Com-
mittee, will be sent by the CI to REC, with a Safety Re-
port Form, and to the Sponsor.
The end of study is defined as database lock once all
data collection is complete. The Sponsor, CI and/or the
SC have the right at any time to terminate the study for
clinical or administrative reasons. The end of the study
will be reported to the Sponsor and REC within 90 days,
or 15 days if the study is terminated prematurely. The PI
will ensure that any appropriate follow up is arranged
for all participants. A summary report of the study will
be provided to the Sponsor and REC within 1 year of the
end of the study.
Ownership of the data arising from this study resides
with the study team and their respective employers. On
completion of the study, the study data will be analysed
and tabulated, and a clinical study report will be
prepared.
The clinical study report will be used for publica-
tion and presentation at scientific meetings. Investiga-
tors have the right to publish orally or in writing the
results of the study.
Summaries of results will also be made available to
Investigators for dissemination within their clinical
areas (where appropriate and according to their
discretion).
Discussion
This early phase study will examine patient responses to
personalised risk information about their risk of having
CRC. The best methods to present personalised risk in-
formation based on age, gender and faecal haemoglobin
concentration will be determined and compared to
current practice i.e. a positive/negative test result. We
will test whether this can lead to truly informed choice,
the effect on intention to have a colonoscopy and thus
potential impact on colonoscopy services, and whether
informed choice can improve patient outcomes/satisfac-
tion and potentially save lives.
Our study will be based on hypothetical scenarios and
intention, rather than actual uptake of colonoscopy.
Thus, we expect to use the results to inform a full-scale
RCT which will evaluate actual uptake of colonoscopy
for Scottish Bowel Screening programme participants. If
successful, the intervention could be low-cost to deliver
at scale, and thus prove cost-effective for introduction
within the national screening programme.
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